Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
China Inflation Cools in July as CPI Misses Forecast, PPI Deflation Eases 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
Japan Posts First Current Account Deficit in 17 Months as Dividend Payments Surge 
Oil Prices Rise as Hormuz Reopening Remains Uncertain 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
US Yen Intervention Unlikely to Deliver Lasting Recovery, Yardeni Says 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
ADNOC Gas Targets Up to $4B Profit in 2026 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
Fujirebio Holding is now doubling down on developing blood tests to detect Alzheimer’s against which blockbuster therapy is expected soon.
The tiny Tokyo-based diagnostics firm, a unit of H.U. Group Holdings, which has a market value of $1.2 billion, developed the first US-approved spinal fluid test for Alzheimer’s.
According to Goki Ishikawa, the CEO of Fujirebio, the firm is boosting its lineup of reagents used to detect Alzheimer’s biomarkers in blood tests. It aims to file these tests for approval in the US as early as 2023.
Ishikawa said that the lineups offered by industry leaders are still limited, so they are rushing to create a solid lineup of tests.
